178 related articles for article (PubMed ID: 26969569)
1. What you cannot get from routine MRI of MS patient and why - The growing need for atrophy assessment and seeing beyond the plaque.
Hartel M; Kluczewska E; Pierzchała K; Adamczyk-Sowa M; Karpe J
Neurol Neurochir Pol; 2016; 50(2):123-30. PubMed ID: 26969569
[TBL] [Abstract][Full Text] [Related]
2. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
Jacobsen CO; Farbu E
Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
[TBL] [Abstract][Full Text] [Related]
3. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
Galego O; Gouveia A; Batista S; Moura C; Machado E
Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
[TBL] [Abstract][Full Text] [Related]
4. Challenges in multiple sclerosis; how to define occurence of progression.
Brinar VV; Barun B
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S30-4. PubMed ID: 24321151
[TBL] [Abstract][Full Text] [Related]
5. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
[TBL] [Abstract][Full Text] [Related]
6. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
7. [Contribution of nuclear magnetic resonance imaging in multiple sclerosis].
Ranjeva JP; Audoin B; Pelletier J; Confavreux C
Rev Prat; 2006 Jun; 56(12):1326-35. PubMed ID: 16948221
[TBL] [Abstract][Full Text] [Related]
8. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
[TBL] [Abstract][Full Text] [Related]
9. [Magnetic resonance in the diagnosis and treatment of multiple sclerosis].
Rovira Cañellas A
Neurologia; 2000; 15(7):288-302. PubMed ID: 11075577
[TBL] [Abstract][Full Text] [Related]
10. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study.
Duan Y; Liu Y; Liang P; Jia X; Yu C; Qin W; Sun H; Liao Z; Ye J; Li K
Eur J Radiol; 2012 Feb; 81(2):e110-4. PubMed ID: 21316170
[TBL] [Abstract][Full Text] [Related]
11. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
[TBL] [Abstract][Full Text] [Related]
12. Cortical pathology and cognitive impairment in multiple sclerosis.
Calabrese M; Rinaldi F; Grossi P; Gallo P
Expert Rev Neurother; 2011 Mar; 11(3):425-32. PubMed ID: 21375447
[TBL] [Abstract][Full Text] [Related]
13. Reduction of brain volume in MS. MRI and pathology findings.
Lycklama à Nijeholt GJ
J Neurol Sci; 2005 Jun; 233(1-2):199-202. PubMed ID: 15949505
[TBL] [Abstract][Full Text] [Related]
14. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no.
Filippi M; Rocca MA
Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411
[No Abstract] [Full Text] [Related]
15. Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis.
Sąsiadek M; Hartel M; Siger M; Katulska K; Majos A; Kluczewska E; Bartosik-Psujek H; Kułakowska A; Słowik A; Steinborn B; Adamczyk-Sowa M; Kalinowska A; Krzystanek E; Bonek R; Serafin Z; Sławek J; Nowacki P; Stępień A; Jóżwiak S; Rejdak K; Selmaj K; Walecki J
Neurol Neurochir Pol; 2020; 54(5):410-415. PubMed ID: 33085075
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis.
Nocentini U; Bozzali M; Spanò B; Cercignani M; Serra L; Basile B; Mannu R; Caltagirone C; De Luca J
Brain Imaging Behav; 2014 Sep; 8(3):378-86. PubMed ID: 22584774
[TBL] [Abstract][Full Text] [Related]
17. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes.
Geurts JJ
Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412
[No Abstract] [Full Text] [Related]
18. Recent developments in imaging of multiple sclerosis.
Poloni G; Minagar A; Haacke EM; Zivadinov R
Neurologist; 2011 Jul; 17(4):185-204. PubMed ID: 21712664
[TBL] [Abstract][Full Text] [Related]
19. Measuring brain atrophy in multiple sclerosis.
De Stefano N; Battaglini M; Smith SM
J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728
[TBL] [Abstract][Full Text] [Related]
20. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.
Steenwijk MD; Geurts JJ; Daams M; Tijms BM; Wink AM; Balk LJ; Tewarie PK; Uitdehaag BM; Barkhof F; Vrenken H; Pouwels PJ
Brain; 2016 Jan; 139(Pt 1):115-26. PubMed ID: 26637488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
